Does Wegovy actually make you lose weight?

What the STEP 1 trial found, and why it was significant

The clearest evidence for how well semaglutide causes weight loss comes from the STEP 1 trial, published in the New England Journal of Medicine. Nearly 2,000 adults with obesity, without type 2 diabetes, were randomised to semaglutide 2.4mg weekly or a placebo, alongside lifestyle support. After 68 weeks, the semaglutide group had lost an average of about 15% of their starting weight. The placebo group lost around 2.4%.

That gap matters. It tells you the drug itself is doing something substantial, not just the diet advice running alongside it. About a third of participants in the active group lost more than 20% of their body weight. Those are outcomes that, until recently, were associated only with bariatric surgery.

The evidence base for semaglutide as a weight-loss medicine has since grown considerably. NICE's appraisal of Wegovy reviewed this data and recommended semaglutide for adults meeting specific clinical criteria, that recommendation is itself a mark of the evidence quality NICE requires before endorsing any medicine.

One honest note: if you are reading this hoping for a simple yes or no, the clinical answer is yes for most people who take it as prescribed, but 'most' is not 'all', and results depend heavily on adherence, diet and how your body responds.

How does semaglutide make you lose weight, what it actually does in the body

Semaglutide is a GLP-1 receptor agonist. GLP-1 is a hormone your gut releases naturally after eating; it signals to the brain that food has arrived and slows the passage of food through the stomach. Semaglutide mimics that hormone, but lasts far longer than the version your body makes, a single weekly injection maintains the effect across seven days.

In practice, people on Wegovy typically notice that food feels satisfying more quickly, cravings are quieter and the mental chatter around eating tends to ease. That is not willpower; it is pharmacology. The brain's appetite centres are receiving a sustained signal that they would normally only get briefly after a meal. You can read more about the underlying mechanism on how Wegovy helps you lose weight.

Weight loss tends to be gradual and consistent rather than dramatic in the first weeks. The titration schedule (starting at a low dose and increasing in roughly monthly steps) is partly for tolerability and partly because the therapeutic effect builds over time. Meaningful loss usually becomes apparent by weeks eight to twelve for most people, though the speed of the effect depends on how the drug interacts with your individual biology, and the timeline varies considerably between individuals.

The key point about how semaglutide produces weight loss is that it addresses biological drivers of appetite, not just behaviour. That is why it works where willpower alone often doesn't.

Who sees the best results, and what the evidence says about individual variation

Clinical trials report averages, and averages hide a wide range of individual outcomes. Some people in STEP 1 lost over 20% of their body weight; others lost considerably less. Factors that appear to influence response include how strictly the reduced-calorie diet is followed, baseline weight, the presence of metabolic conditions, and how the treatment is managed over time.

Wegovy's licence covers adults with a BMI of 30 or above, or a BMI from 27 upwards alongside at least one weight-related condition such as high blood pressure or raised cholesterol. Lower thresholds apply for some ethnic backgrounds under UK clinical guidance. Meeting those numbers, though, is a starting point rather than a guarantee, a prescriber looks at the whole picture before deciding whether treatment is appropriate.

If you are considering Wegovy and wondering whether it would work for you specifically, that is exactly the kind of question our prescribers work through during a consultation. Practical tips on getting the most from treatment are also worth reading alongside this, since lifestyle factors genuinely affect outcomes.

For a broader look at weight-loss treatment options available in the UK, including how Wegovy compares to other licensed medicines, our overview covers the key distinctions in plain language.

Side effects, safety and what to watch for

The evidence on efficacy and the evidence on side effects come from the same trials, so it is worth covering both together. The most frequently reported effects of semaglutide are gastrointestinal: nausea, constipation, diarrhoea, indigestion and reflux appear commonly, particularly in the first few weeks or after a dose increase. For most people these settle as the body adjusts.

More serious but uncommon effects include acute pancreatitis, severe, persistent stomach pain that may spread to the back is a reason to seek urgent medical attention. The MHRA's Yellow Card scheme is there for reporting suspected side effects, and our prescribers will talk you through what to watch for before treatment begins.

Wegovy is not recommended during pregnancy, whilst breastfeeding, or for people actively trying to conceive. It is not licensed for anyone under 18. Women using oral contraceptives should note that for tirzepatide there is specific guidance around additional contraceptive cover, for semaglutide the evidence picture differs, but it is worth discussing contraception with your prescriber at the outset.

The NHS medicines information page for semaglutide has a clear summary of side effects and precautions in plain English, and is a good companion to the Patient Information Leaflet that comes with the pen.

If you are curious about what treatment through a regulated UK pharmacy looks like in practice, our pharmacy's clinical approach is set out on our about page. When you're ready to talk through your own situation, you can speak to our prescribers through a free consultation.